Business / Finance

RSS

Thomson Reuters welcomes GenoSpace to Life Sciences Partner Ecosystem

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced that GenoSpace joined its Life Sciences Partner Ecosystem.

16 Aug 2012

Quintiles acquires premier provider of genomics testing and analysis

To help biopharmaceutical companies dramatically improve drug development productivity and deliver greater value, Quintiles today announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government and non-profit customers.

13 Aug 2012

Verastem second quarter net loss increases to $6.8 million

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

13 Aug 2012

SAIC acquires maxIT Healthcare

Science Applications International Corporation (SAIC) today announced it has completed the acquisition of maxIT Healthcare Holdings, Inc., a leading healthcare IT (Information Technology) consulting firm based in Westfield, Ind.

13 Aug 2012

Taro, Sun Pharma enter merger agreement

Sun Pharmaceutical Industries Ltd. and Taro Pharmaceutical Industries Ltd. announced today that they have entered into a merger agreement together with certain affiliates of Sun Pharma.

13 Aug 2012

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.

10 Aug 2012

Trauma: spending more money doesn’t translate to higher survival rates

A large-scale review of national patient records reveals that although survival rates are the same, the cost of treating trauma patients in the western United States is 33 percent higher than the bill for treating similarly injured patients in the Northeast. Overall, treatment costs were lower in the Northeast than anywhere in the United States.

10 Aug 2012

Provista, Physician Strategy Group at USPI partner to deliver supply chain services

United Surgical Partners International's (USPI) Physician Strategy Group (PSG) and Provista, LLC announced today that they are working together to deliver supply chain services to over 9,000 physician customers who perform procedures at surgical facilities centers operated by USPI. The program, called Purchasing Plus, is expected to help those physicians save 10-15% on supplies, services, and capital equipment.

9 Aug 2012

PAREXEL board approves stock repurchase program

PAREXEL International Corporation announced today that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $200 million of the Company's common stock, subject to the consent of the Company's lenders.

From Parexel 9 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Bristol-Myers Squibb completes tender offer for all outstanding shares of Amylin

Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. at a purchase price of $31.00 per share.

8 Aug 2012